Cytokines released from activated mono-
Although most cases of inflammatory bowel disease can be classified as either ulcerative colitis or Crohn's disease on the basis of clinical and histopathological appearances, many of the inflammatory mechanisms involved at the tissue level in the two conditions are identical.' Serum concentrations of correlates of inflammationsuch as C reactive protein, cL, acid glycoprotein (or orosomucoid), and neutrophil elastase -have been extensively studied, largely because these objective parameters may help assess the inflammatory process either in individual patients or in clinical trials. This is particularly useful in Crohn's disease where the correlation between symptoms and the presence of inflammation may be poor. In comparisons between ulcerative colitis and Crohn's disease, differences in the circulating levels of some laboratory markers have emerged, even when attempts are made to compare patients with apparently similar degrees of clinical severity. Thus C reactive protein levels,' serum amyloid A associated protein,3 and neutrophil elastase4 are generally significantly higher during active Crohn's disease than during active ulcerative colitis, although ol1 acid glycoprotein and oL1-antichymotrypsin' show a similar increase.
There may be relatively trivial explanations for the differences in serum levels of parameters of inflammation between the two conditions. For example, the lower elastase concentrations found in ulcerative colitis may merely reflect the more superficial distribution of inflammation, compared with Crohn's disease, and consequent loss of elastase released from polymorphonuclear leukocytes into the gut lumen rather than into the circulation. An alternative explanation is that these differences reflect differences in the nature of the inflammatory processes occurring in these two conditions. Differing inflammatory processes might reflect different aetiologies of ulcerative colitis and Crohn's disease; alternatively, even if the initiating factor for inflammatory bowel disease is the same, a differing genetic background might predispose to expression of a particular form of inflammatory response, resulting in development of one or other form of inflammatory bowel disease.
Recent studies have begun to elucidate the process leading to the generation of serum proteins such as C reactive protein and cl1 acid glycoprotein, showing the hepatic origin of these proteins, and that hepatic synthesis of these acute phase reactants is rapidly up-regulated in response to various cytokines released from inflammatory cells. In particular, the role of the mediators interleukin 1 (IL 1), tumour necrosis factor ca (TNF et), and interleukin 6 (IL 6) (monocytic hepatocyte stimulating factor) have been emphasised."-" In inflamed tissue, the generation of this family of polypeptides from macrophages is substantially enhanced. In the context of inflammatory bowel disease, the noted differences in circulating concentrations of acute phase proteins between Crohn's disease and ulcerative colitis may reflect qualitative differences in the cytokines produced in inflamed tissue, or again, reflect trivially, differences only in the number of macrophages involved in the inflammatory process.
We therefore investigated the ability of cells of the monocyte-macrophage lineage from patients with ulcerative colitis and Crohn's disease, to release the cytokines IL 113 and TNF (x. We quantified release of these cytokines from peripheral blood monocytes during both active and quiescent disease, and compared the results with those from normal control subjects. Patients with ulcerative colitis were assessed as being in remission or having mild, moderate, or severe disease (Truelove and Witts, 1955).13 There were 10 patients in the ulcerative colitis group who had active disease and 11 patients had inactive disease, with one patient whose disease subsequently became active. Of the patients in the active group, six were mildly active and five had moderately active disease. In terms of disease distribution, four patients had pancolitis, 12 had left colon involvement (of which two had proctosigmoiditis, eight had involvement of the rectum, sigmoid, and descending colon, and two had involvement of the rectum, sigmoid, descending, and transverse colon), and five had disease limited to the rectum.
TREATMENT
In the Crohn's disease group, nine patients were not on treatment. Two patients were receiving sulphasalazine and five were being treated with 5-aminosalicylic acid; one of these was also receiving prednisolone. One patient was receiving fluticasone propionate, four patients were receiving prednisolone alone, and one patient was treated with prednisolone and azathioprine. In the ulcerative group, three patients were not on treatment. Nine patients were receiving sulphasalazine and six were on treatment with 5-aminosalicylic acid; one of these was also receiving prednisolone. One patient received steroid enemas, one received prednisolone alone, and one received treatment with prednisolone and azathioprine. 
Results

PERIPHERAL BLOOD MONOCYTES
The number of peripheral blood monocytes was mean (SEM) 3-2 (0.6) x 105/ml for ulcerative colitis, 3.6 (0.6)x 105/ml for Crohn's disease, and 3.3 (0.3)x 105/ml for normal controls, with no significant differences between the three groups. However, among the patients with inflammatory bowel disease, those who had active inflammation (4-0 (0-7)x 10/ml; p<0.05 Wilcoxon) had greater monocyte counts than those without active disease (2-8 (0-2)x 105/ml).
In patients with active ulcerative colitis (4.1 (11)x1O5/ml; p<OOl Wilcoxon) the number of peripheral blood monocytes is significantly higher than in patients with inactive disease (2-4 (0.3)x10'/ml). In active Crohn's disease (3.9 (1-1) x 105/ml), the number of peripheral blood monocytes showed a similar trend compared with patients with inactive disease (3-2 (0-3) x 105/ml) but the difference did not reach statistical significance. IN The study of acute phase proteins in inflammatory bowel disease is relevant from two points of view. These proteins provide valuable laboratory parameters for assessing disease activity, and this has been the main concern in this study. The physiological relevance of acute phase reactant is not completely understood. A major function may be to counterbalance indirectly the toxic actions of mediators of inflammation on 41 43 tissue damage.
Since identical numbers of monocytes were employed for each patient in this study, it seems that the differences in cytokine profile reported here between patients with Crohn's disease and ulcerative colitis reflect an intrinsic, perhaps genetically determined, difference in the ability to produce cytokines rather than a quantitative difference in the number of macrophages activated at the disease site. Although the data obtained were from studying isolated peripheral blood monocytes, relevance to the gut may be inferred since peripheral blood monocytes are precursors of tissue macrophages. Monocytes thus provide an opportunity to study the mononuclear phagocytes cell line before the monocytes migrate from the blood into the bowel mucosa where they became activated. These immunological responses seen in the peripheral blood are events that mirror systemic activation in the gut. Mucosal cytokine production is an important aspect of the mucosal immune system which plays a key role in gut inflammation in both Crohn's disease and ulcerative colitis. These findings add further evidence to support the immunological basis of the pathogenesis of inflammatory bowel disease. They do not con-flict with the view that Crohn's disease and ulcerative colitis are part of a spectrum of a single disease process manifesting as different clinical entities, but suggest that the difference in inflammatory events reflects inter alia genetically determined properties of the macrophage series. 
